The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) announced the recipients of the 2026 Stephenson Global Scholar Grants. In partnership...
QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour...
Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 m...
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V. announced that they have agreed to update their long-term relat...
Award supports an iPSC and AI-driven drug discovery program targeting the leading cause of death in DMD patients Greenstone Biosciences, a biote...
The U.S. Food and Drug Administration granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral t...
Biogen Inc. announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing sm...
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus A...
Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the li...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinica...
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population PSMAddition updated results show Pluvicto r...
Artificial intelligence is transforming the role of advanced practice providers (APPs) by streamlining documentation, simplifying clinical workfl...
-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form...
© 2026 Biopharma Boardroom. All Rights Reserved.
